ZILAD Zila (MM)

Zila, Inc. (NASDAQ:ZILAD) today announced that ViziLite๏ฟฝ Plus with TBlue๏ฟฝ, its flagship oral cancer screening product, will be prominently featured at the British Dental Trade Association (BDTA) Dental Showcase in London on October 2-4, 2008. The BDTA meeting will be held at ExCeL London, the international exhibition and conference centre. The BDTA is attended by more than 10,000 dental professionals and has over 300 companies exhibiting. Early detection of oral cancer will be a focus at the Showcase with presentations from the Mouth Cancer Foundation and members of the dental profession. A presentation featuring ViziLite Plus as a new screening technology in the UK will be presented on Thursday and repeated again on Friday on the exhibition floor. Richard Horner, recognized UK mouth cancer awareness and prevention advocate, stated, ๏ฟฝrecent studies indicate that new cases of oral and oropharyngeal cancer continue to rise across the United Kingdom among all ages and both sexes.๏ฟฝ He went on to state, ๏ฟฝthe timely introduction of products like ViziLite Plus further helps to bring focus on the identification of cancers and suspicious lesions earlier than visual examination alone.๏ฟฝ ViziLite Plus is currently available in the UK and Ireland exclusively through a distribution partnership with Panadent Limited. Orders for ViziLite Plus will be taken at the Panadent booth during Showcase hours. About Oral Cancer and ViziLite Plus Oral cancer is the sixth leading cause of cancer worldwide, and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection, yet prior to the introduction of ViziLite Plus the only screening tools available were the manual and visual exam, which helps explain why the mortality and morbidity associated with oral cancer have not markedly improved in the past 40 years. Worldwide clinical trials have demonstrated that the conventional visual/tactile examination may fail to identify up to 40% of cancers and precancers. ViziLite Plus, an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented vital tissue dye (TBlue), helps dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam takes only minutes and is totally painless and non-invasive. Oral Cancer Risk factors: -- age - adults, especially those 40 years of age and older -- tobacco use - particularly if combined with heavy alcohol consumption -- heavy alcohol consumption -- excessive sun exposure to the lips -- sexually transmitted human papillomavirus (HPV) About Zila, Inc. Zila, Inc., is a fully integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. ViziLite๏ฟฝ Plus with TBlue๏ฟฝ, the company's flagship product for the early detection of oral abnormalities that could lead to cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent๏ฟฝ Professional Powered Brush, the Pro-Select Platinum๏ฟฝ ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely affect revenue, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2007 and Form 10-Q for the quarter ended April 30, 2008. For more information about the company and its products, please visit www.zila.com.